Please assess the completion status of the following clinical trial:

Trial Title: Changes in Myocardial Iron After Iron Administration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with ambulatory chronic heart failure~* Older than 18 years~* Patients in NYHA class II-III on optimal background therapy (as determined by the investigator) for at least 4 weeks with no dose changes of HF drugs during the last 2 weeks (with the exception of diuretics)~* Elevated natriuretic peptides levels (NT-proBNP \>400 pg/ml) at the screening visit~* Left ventricle ejection fraction \<50% documented in the last 12 months~* Iron deficiency defined as: serum ferritin level \<100 μg/L or ferritin level 100-299 μg/L when TSAT is less than 20%, and hemoglobin \<15 g/dL (all at screening)~* Participant is willing and able to give informed consent for participation in the study~Exclusion Criteria:~* Known sensitivity to any of the products to be administered per protocol.~* History of acquired iron overload.~* Severe valve disease, or being scheduled for cardiac surgery within the next 30 days.~* Acute myocardial infarction or acute coronary syndrome, transient ischemic attack, or stroke within the last 3 months prior to randomization.~* Coronary artery bypass graft, percutaneous intervention (e.g. cardiac, cerebrovascular, and aortic; diagnostic catheters are allowed), or major surgery, including thoracic and cardiac surgery, within the last 3 months prior to randomization.~* Ischemic heart disease scheduled for revascularization procedures within the next 30 days.~* HF scheduled for cardiac resynchronization therapy within the next 30 days.~* Patients with active bleeding in the last 30 days.~* Known active infection or active malignancy.~* Subject at an immediate need of transfusion or hemoglobin ≥15 g/dL.~* Anemia due to reasons other than iron deficiency~* Immunosuppressive therapy or renal dialysis~* History of erythropoietin, intravenous iron therapy, and blood transfusion in the previous 12 weeks.~* Oral iron therapy at doses \>100 mg/day in previous 1 week prior to randomization.~* Subjects with an immediate need for transfusion.~* Pregnant or breastfeeding women.~* Subject of childbearing potential who is not willing to use adequate contraceptive precautions during the study and for up to 5 days after the last scheduled dose of study medication.~* Subject currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study, or subject is receiving other investigational agent(s).~* Any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intravenous ferric carboxymaltose (Type: ACTIVE_COMPARATOR): Ferric Carboxymaltose solution \[Ferinject® (FCM), Vifor Pharma (Glattbrugg, Switzerland)\] will be given as a perfusion of 20 mL (which is the amount of FCM that is equivalent to 1000 mg of iron) diluted in a sterile saline solution (0.9% weight/volume (w/v) NaCl) administered over at least 15 min.
- Normal saline (Type: PLACEBO_COMPARATOR): Normal saline (0.9% weight/volume (w/v) NaCl) administered as per the instructions for active therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).